I discuss the impact that the U.S. Drug Enforcement Administration’s potential reclassification of cannabis would affect Georgia’s medical cannabis industry in his article published by Cannabis Industry Journal.
In particular, I consider three key areas of impact:
(1) How Georgia medical cannabis distributors would operate within this new regulatory framework;
(2) How this change would affect registered Georgia patients who are either currently purchasing medical cannabis or are planning to do so; and
(3) Whether this reclassification would cause big pharmaceutical companies to enter Georgia’s medical cannabis market, and if so, how.
/Passle/5fe0c4f453548a10fc881e09/MediaLibrary/Images/2025-10-09-14-47-09-526-68e7caed09520928935393cf.png)
/Passle/5fe0c4f453548a10fc881e09/SearchServiceImages/2025-09-30-13-12-56-565-68dbd758f6347a2c4b9a81ab.jpg)
/Passle/5fe0c4f453548a10fc881e09/SearchServiceImages/2025-09-02-15-10-27-674-68b708e3a631091b7967ef21.jpg)